University of Minnesota, Twin Cities, Minneapolis, MN, USA.
J Cataract Refract Surg. 2010 Nov;36(11):1887-96. doi: 10.1016/j.jcrs.2010.05.028.
To assess changes in patient-reported outcomes, satisfaction, vision quality, and visual acuity after bilateral implantation of multifocal intraocular lenses (IOLs) with a 3.00 D addition (add) in cataract patients.
Twelve study centers, United States.
Randomized multicenter clinical trial.
In this 6-month trial, cataract patients had bilateral implantation of the AcrySof IQ ReSTOR +3.0 IOL (model SN6AD1). Patient-reported outcomes were collected using the Cataract TyPE questionnaire. Clinical outcomes included uncorrected near (UNVA), uncorrected intermediate (UIVA), and uncorrected distance (UDVA) visual acuities.
The study comprised 147 patients. From preoperatively to 6 months postoperatively, the mean UDVA improved from 0.45 logMAR (approximate Snellen, 20/56) to 0.04 logMAR (20/22 Snellen), the mean UIVA from 0.56 logMAR (20/73) to 0.17 logMAR (20/30), and the mean UNVA from 0.62 logMAR (20/83) to 0.10 logMAR (20/25); all improvements were clinically and statistically significant (P<.0001). There was also a statistically significant improvement in patient satisfaction with uncorrected vision (P<.0001). Clinically and statistical significant reductions occurred in trouble with vision (daytime and nighttime), trouble with glare, limitations with UDVA, limitations with UNVA, and limitations in social activities (P<.0001).
Bilateral implantation of multifocal intraocular lenses (IOLs) with a 3.00 D add produced statistically significant and clinically relevant postoperative improvements in UNVA, UIVA, and UDVA. Commensurate significant postoperative improvements were observed in the patient-reported uncorrected functional vision, satisfaction with uncorrected vision, and social activities.
评估白内障患者双侧植入 3.00 D 附加(add)的多焦点人工晶状体(IOL)后患者报告的结果、满意度、视觉质量和视力的变化。
美国 12 个研究中心。
随机多中心临床试验。
在这项为期 6 个月的试验中,白内障患者接受了 AcrySof IQ ReSTOR +3.0 IOL(型号 SN6AD1)的双侧植入。使用白内障类型问卷收集患者报告的结果。临床结果包括未矫正近视力(UNVA)、未矫正中间视力(UIVA)和未矫正远视力(UDVA)视力。
该研究共纳入 147 例患者。从术前到术后 6 个月,平均 UDVA 从 0.45 logMAR(近似 Snellen,20/56)改善至 0.04 logMAR(20/22 Snellen),平均 UIVA 从 0.56 logMAR(20/73)改善至 0.17 logMAR(20/30),平均 UNVA 从 0.62 logMAR(20/83)改善至 0.10 logMAR(20/25);所有改善均具有临床和统计学意义(P<.0001)。未矫正视力(P<.0001)的患者满意度也有统计学显著提高。在视力障碍(白天和夜间)、眩光障碍、UDVA 限制、UNVA 限制和社交活动限制方面,均观察到具有临床和统计学意义的显著减少(P<.0001)。
双侧植入 3.00 D 附加的多焦点人工晶状体(IOL)可显著改善 UNVA、UIVA 和 UDVA,具有统计学意义和临床相关性。在未矫正的功能性视力、未矫正视力的满意度和社交活动方面,也观察到了相应的显著术后改善。